Biovica secures Japanese patent allowance for DiviTum TKa use during immunotherapy treatment

• Biovica received a Notice of Allowance in Japan for a patent covering use of TKa to monitor response during ongoing immune checkpoint inhibitor treatment.
• The allowance builds on a recently granted Japanese patent covering TKa use to identify patients more likely to benefit before treatment.
• The combined protection extends coverage from pre-treatment stratification to in-therapy monitoring, supporting Biovica’s pharma services and companion diagnostics strategy.
• Biovica cited corresponding protection in Europe, with patent efforts continuing in the US and China.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biovica International AB published the original content used to generate this news brief on July 16, 2026, and is solely responsible for the information contained therein.